Sign in
Taking people in GermanyPhase 3

Tests lenacapavir with two antibody treatments for adults with HIV-1 on stable pills

Tests switching from pill treatment to lenacapavir and two antibodies in adults with HIV-1.

Key facts

Who runs it
Gilead Sciences Inc.
Where
Berlin, Bonn, Cologne, Essen, Frankfurt Am Main, Hamburg, Köln, Mannheim, and Munich, GermanySee the 9 sitesAlso in 5 other countries, 29 sites
Registry title
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens
Status
Recruiting
Phase
Phase 3
People taking part
183 people, planned
Started
10 Aug 2026
Expected to end
31 May 2033
Type of study
Interventional
Record updated
6 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults living with HIV-1 whose virus is well controlled on a stable oral treatment. They would switch to lenacapavir, teropavimab and zinlirvimab twice a year, or stay on their oral treatment.

Age
18 years or older
Sex
All sexes can join
Disease stage
HIV-1 virus level below 50 copies/mL at screening, and on stable oral HIV treatment for at least 6 months. No past opportunistic infection or illness that signals Stage 3 HIV disease.
Earlier treatment
Must be on stable oral HIV treatment for at least 6 months. Cannot have used lenacapavir, another broadly neutralizing antibody for HIV-1, ibalizumab, fostemsavir, maraviroc, or long-acting injectable cabotegravir or rilpivirine.
Biomarker or test result
The HIV must be sensitive to both teropavimab and zinlirvimab on a screening lab test (IC90 of 2 µg/mL or lower for each). Body weight must be at least 35 kg (77 lb).

Main reasons for not taking part

  • Chronic hepatitis B infection, or hepatitis C with detectable virus
  • Active tuberculosis or other serious infection needing treatment in the last 30 days
  • Pregnant, breastfeeding, or planning pregnancy or breastfeeding during the study
  • Severe kidney problems (eGFR below 30 mL/min) or severe liver disease
  • Immune-suppressing treatment within 4 weeks of screening, apart from one short steroid course of 7 days or less

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • General G1. Participants assigned male or female at birth, 18 years of age or older at screening, able to understand and give written informed consent and comply with treatment and follow-up
  • G2. Participants assigned female at birth who are of childbearing potential and engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception as described in Appendix 11.4
  • Medical History/Physical Characteristics MH1. Body weight ≥ 35 kg at screening
  • MH2. HIV-1 susceptibility results from screening meeting specific criteria: Proviral phenotypic susceptibility to both TAB and ZAB by the investigational PhenoSense HIV mAb Assay (Labcorp Monogram Biosciences) at screening. TAB phenotypic susceptibility is defined as IC90 ≤ 2 µg/mL; ZAB phenotypic susceptibility is defined as IC90 ≤ 2 µg/mL
  • MH3. Plasma HIV-1 RNA levels < 50 copies/mL at screening (SV2)
  • MH4. At least 1 documented HIV-1 RNA level measured between 6 months and 12 months (+ 2 months) prior to screening (SV1). This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL). A single virologic elevation of ≥ 50 copies/mL and < 400 copies/mL (transient detectable viremia or “blips”) prior to screening are acceptable if the subsequent plasma HIV-1 RNA level is < 50 copies/mL
  • MH5. A plasma HIV-1 RNA test < 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL) within the last 6 months prior to SV1. If > 1 plasma HIV-1 RNA measurements in the last 6 months prior to screening are available, all must be < 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL)
  • MH6. On a stable oral ART for ≥ 6 months prior to screening. A change in ART regimen ≥ 3 months prior to the screening visit for reasons other than VF (eg, tolerability, simplification, DDI profile) is allowed; participants with a change in ART regimen ≥ 3 months prior to screening must have been on the regimen for ≥ 3 months prior to screening, and all HIV-1 RNA measurements in that period must be < 50 copies/mL. There are no permitted changes to ART regimens between SV1 and Day 1
  • Laboratory Assessments LA1.For participants of childbearing potential, a negative serum pregnancy test at screening, prior to Day 1 randomization, and enrollment (per Appendix 11.4). A negative urine pregnancy test is required on Day 1 visit prior to the dosing of study drugs

Who cannot take part

  • Prior/Concurrent Therapy or Clinical Study Experience PT1. Prior use of, or exposure to, LEN or a bNAb for HIV-1
  • PT2. Prior use of, or exposure to, ibalizumab fostemsavir, or maraviroc
  • PT4. Treatment with immunosuppressant therapies (eg, corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies) within 4 weeks of screening (with the exception of a single short course of corticosteroids lasting ≤ 7 days) or have a comorbid condition with an anticipated need ongoing immunosuppressive treatment during the study
  • PT5. Requirement for ongoing therapy with or prior use of any prohibited medications listed in Section 5.3.1
  • PT6. Participation or planned participation in any other clinical study (including observational studies) without prior approval from the sponsor
  • PT7. Prior use of, or exposure to, LA injectable CAB or LA injectable RPV
  • DA2. Chronic HBV infection, as determined by either: Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV core antibody status, at the screening visit. Positive HBV core antibody and negative HBV surface antibody, regardless of HBV surface antigen status, at the screening visit. Note: Participants found to be susceptible to HBV infection (eg, negative hepatitis B surface antibody at the screening visit, regardless of prior HBV vaccination history) should be recommended to receive an HBV vaccination. Those who remain non immune will receive regular testing for HBV
  • Other Exclusion Criteria E1. Have other concurrent medical or psychiatric conditions, or prior therapies that, in the investigator’s opinion,B10may be likely to confound study interpretation, prevent completion of study procedures and follow-up examinations, or poses an undue risk to the participant
  • MC3. Active, serious infections (other than HIV-1) requiring therapy < 30 days prior to randomization
  • MC5. Acute hepatitis of any cause < 30 days before randomization
  • MC8. Have poor venous access that would limit phlebotomy or IV infusion of study drugs
  • Medical Conditions/History MC1. History of an opportunistic infection or illness indicative of Stage 3 HIV disease
  • Diagnostic Assessments DA1. Hepatitis C virus (HCV) antibody positive and HCV RNA detectable
  • MC2. Known hypersensitivity to the study intervention, its metabolites, or formulation excipients
  • DA3. Severe renal impairment-estimated glomerular filtration rate < 30 mL/min according to the Cockcroft-Gault formula {Cockcroft 1976}
  • MC4. Active tuberculosis infection
  • MC6. History of, or current clinical decompensated liver cirrhosis (eg, ascites, encephalopathy, or variceal bleeding) or severe hepatic impairment (Child-Pugh Class C)
  • MC7. Active malignancy requiring acute systemic therapy
  • DA5. Any of the following laboratory values at screening: A) Alanine aminotransferase > 5 × upper limit of normal (ULN). B) Direct bilirubin > 1.5 × ULN. C) Platelets < 50,000/mm3. D) Hemoglobin < 8.0 g/dL
  • PT3. Baseline regimen consisting of monotherapy with any single ARV
  • PT8. Current use of, or exposure to, nevirapine or zidovudine
  • DA4. Abnormal electrocardiogram (ECG) at the screening visit that is clinically significant, as determined by the investigator.B10
  • E2. Participants under guardianship, curatorship, or legal protection may not participate in the study.B10
  • MC9. Participants assigned female sex at birth who are pregnant, nursing a child (breastfeeding), or plan to become pregnant, or begin nursing (breastfeeding) a child during the study

Where in Germany

Also in 5 other countries, 29 sites

  • Epimed Gesellschaft fuer epidemiologische und klinische Forschung in der Medizin mbHBerlin, GermanyTaking people
  • Universitaetsklinikum Bonn AöRBonn, GermanyTaking people
  • Universitaetsklinikum Koeln AöRCologne, GermanyTaking people
  • Universitaetsklinikum Essen (AoR)Essen, GermanyTaking people
  • Infektio Research GmbH & Co. KGFrankfurt Am Main, GermanyTaking people
  • ICH Study Center Gmbh & Co. KGHamburg, GermanyTaking people
  • Praxis am EbertplatzKöln, GermanyTaking people
  • Mannheimer Onkologie PraxisMannheim, GermanyTaking people
  • MVZ Munchen Am GoetheplatzMunich, GermanyTaking people

About the trial

What the trial wants to find out

To evaluate the efficacy of switching to the regimen of LEN, TAB, and ZAB versus continuing an oral SBR in virologically suppressed PWH as determined by the proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 52.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens
Plain-language title
Tests lenacapavir with two antibody treatments for adults with HIV-1 on stable pillsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
6 October 2026